Intervention
UBX1325
Executive intelligence snapshot
Current reviewed view
The sponsor reported a non-inferiority miss alongside maintained mean visual acuity and later exploratory supportive observations.
This profile includes 2 reviewed relationship(s) and 7 reviewed source(s).
This view is bounded by reviewed evidence and does not provide a recommendation or a claim beyond the stated review date.
Evidence state
Source-reviewed
Evidence state
What the evidence supports
The sponsor reported a non-inferiority miss alongside maintained mean visual acuity and later exploratory supportive observations.
Evidence boundary
Key limitations
- Visual acuity was broadly maintained and the safety profile remained favorable; the record does not establish mechanism failure.
Does not establish efficacy, mechanism falsification, approval, utility, rejuvenation, or investment attractiveness.
Not established
Key unknowns
- Dose, route, population, and outcomes not recorded in this reviewed profile remain unknown.
The reviewed evidence does not resolve this dimension beyond the recorded boundary.
Intelligence connections
Related intelligence
Reviewed source layer
Evidence & sources
These cards show only metadata present in the reviewed source registry.
Reviewed source
Reviewed source metadata is limited.
bibliographic index
Multifocal Electroretinography Changes after UBX1325 Treatment in Neovascular Age-Related Macular Degeneration
PubMed
Reference: 39337030
Reviewed: 2026-08-06
Reviewed source
Reviewed source metadata is limited.
Reviewed source
Reviewed source metadata is limited.
Reviewed source
Reviewed source metadata is limited.
filing system
Unity Biotechnology, Inc. 2024 Annual Report
U.S. SEC EDGAR
Reference: 1463361
Reviewed: 2026-08-06
trial registry
UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
ClinicalTrials.gov
Reference: NCT05275205
Reviewed: 2026-08-06
Technical provenance
- Object key
intervention:LNPG-ENT-c0e87e1e-e35f-420e-adc5-25439ab7c5a6- Source release
LNPG-REL-20260807-027- Mapping version
0.2.0- Presentation release
LNPG-REL-20260808-037- Projection hash
37a219bc7a462bdc84b3d4e3e9c0164a31a30c6b1c879eecbb13600a51f899e0
Source identifiers
LNPG-SRC-267009f7-a006-4adc-a8b6-18fbb89b2574LNPG-SRC-3b165d43-b8d9-4956-aaa6-4b01460d6544LNPG-SRC-5a15692d-c9aa-4d2d-a349-14831bd61076LNPG-SRC-c601f69e-d6a0-4336-a95c-f06a366375f4LNPG-SRC-c6cddcf0-4b0d-4d37-9b4c-9665f7e9f4c0LNPG-SRC-d9a27303-442b-423c-b752-95cf87597c15LNPG-SRC-df3da47f-0297-4219-8f9d-5bb050be51a8
Directed relationship identities
edge:00195—intervention_exactly_links_companyedge:00202—intervention_tested_in_trial
Scores are not displayed because no score methodology is qualified for this profile.
Presentation contract
- Snapshot mode
DIRECT_GOVERNED_SUMMARY